Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
08 févr. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to...
Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member
03 févr. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to...
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
01 févr. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
24 janv. 2022 10h19 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
18 janv. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology...
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
13 janv. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology...
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
10 janv. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
The new serotonin receptor model (5-HT2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules. DENVER, Jan. 10, 2022 (GLOBE...
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
07 janv. 2022 16h30 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology...
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
22 déc. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
09 déc. 2021 10h41 HE
|
Mydecine Innovations Group Inc.
DENVER, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...